Stent Makers, Interventionists Downplay Impact Of BARI 2D Data
This article was originally published in The Gray Sheet
Executive Summary
There is little debate that BARI 2D trial data unveiled last week affirmed that percutaneous coronary intervention does not extend the lives of patients with type 2 diabetes and stable ischemic heart disease, but stent manufacturers and interventionalists are scratching their heads as to why anybody would be surprised